Cargando…
Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation
CRISPR-Cas9-based therapeutic genome editing approaches hold promise to cure a variety of human diseases. Recent findings demonstrate pre-existing immunity for the commonly used Cas orthologs from Streptococcus pyogenes (SpCas9) and Staphylococcus aureus (SaCas9) in humans, which threatens the succe...
Autores principales: | Essawi, Khaled, Hakami, Waleed, Naeem Khan, Muhammad Behroz, Martin, Reid, Zeng, Jing, Chu, Rebecca, Uchida, Naoya, Bonifacino, Aylin C., Krouse, Allen E., Linde, Nathaniel S., Donahue, Robert E., Blobel, Gerd A., Gerdemann, Ulrike, Kean, Leslie S., Maitland, Stacy A., Wolfe, Scot A., Metais, Jean-Yves, Gottschalk, Stephen, Bauer, Daniel E., Tisdale, John F., Demirci, Selami |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236215/ https://www.ncbi.nlm.nih.gov/pubmed/37273902 http://dx.doi.org/10.1016/j.omtm.2023.04.004 |
Ejemplares similares
-
Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model
por: Uchida, Naoya, et al.
Publicado: (2016) -
Comparison of busulfan and total body irradiation conditioning on hematopoietic clonal dynamics following lentiviral gene transfer in rhesus macaques
por: Abraham, Diana M., et al.
Publicado: (2022) -
Low-Dose Busulfan Reduces Human CD34(+) Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice
por: Leonard, Alexis, et al.
Publicado: (2019) -
Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders
por: Uchida, Naoya, et al.
Publicado: (2019) -
Preclinical evaluation for engraftment of CD34(+) cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models
por: Uchida, Naoya, et al.
Publicado: (2021)